MedTrace Logo

Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit

NCT00177931 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2015-12-17

No results posted yet for this study

Summary

The purposes of this study are to:

I. Characterize the plasma concentration-time profile of cefepime in liver transplant patients to determine the pharmacokinetic parameters in this patient population.

II. Perform stochastic modeling using the population pharmacokinetic parameters obtained in Specific Aim I to determine the ideal dose and dosing regimen of cefepime required to attain predetermined therapeutic targets in liver transplant patients.

Conditions

  • Evidence of Liver Transplantation

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Brian Potoski, PharmD · University of Pittsburgh Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00177931 on ClinicalTrials.gov